Liminatus Pharma Inc
Research Liminatus Pharma Inc (LIMN) on Bullrun: market cap USD 77.28K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLIMN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 77.28K
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.41M
- Free cash flow-USD 970.00K
Valuation Snapshot
latest market cap is USD 77.28K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.21M | -USD 9.98M | n/a | -0.43 | USD 337.66K | USD 1.44M | -USD 9.81M |
| FY2024 | USD 0 | -USD 3.55M | -USD 1.45M | n/a | -0.2 | USD 0 | USD 19.97M | -USD 19.34M |
| FY2023 | USD 0 | -USD 4.98M | -USD 3.35M | n/a | -0.19 | USD 434.00K | USD 16.05M | USD 0 |
| FY2022 | USD 0 | -USD 2.93M | -USD 869.00K | n/a | -0.11 | USD 5.05M | USD 16.50M | USD 0 |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 77.28K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 16.51M | n/a | n/a | n/a |
About Liminatus Pharma Inc
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Liminatus Pharma Inc's market cap?
Liminatus Pharma Inc's market capitalization is USD 77.28K.
What does Liminatus Pharma Inc do?
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.